MRTX - Mirati Therapeutics GAAP EPS of -$2.49 beats by $0.40 revenue of $16.4M misses by $2.83M
2023-11-06 11:48:57 ET
More on Mirati Therapeutics
- Mirati Therapeutics: Anatomy Of A Long Simmering Buyout
- Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud
- Mirati: Expansion Of Adagrasib With sNDA And Combination Studies
- Bristol-Myers was only firm that made real bid for Mirati Therapeutics; BMY offered $140/shr in April 2022
- Will more bidders emerge or CVR ever be paid in Mirati takeover deal?
For further details see:
Mirati Therapeutics GAAP EPS of -$2.49 beats by $0.40, revenue of $16.4M misses by $2.83M